Barclays lowered the firm’s price target on Exelixis to $24 from $25 and keeps an Overweight rating on the shares. The analyst says Q2 Cabozantinib sales beat consensus.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL: